Divalproex Sodium 250 mg & 500 mg (Sustained Release)

Get a Price/Quote

Divalproex Sodium 250 mg & 500 mg (Sustained Release) Specification

Drug Type
Specific Drug

Ingredients
Divalproex Sodium 250 mg & 500 mg

Physical Form
Tablets

Function
Other

Recommended For
Epilepsy, Migraine, Mania

Dosage
Epilepsy: Initial 10-15 mg/kg/day in divided dose if necessary may increase by 5-10 mg/kg/week. Migraine: 500 mg once daily for 1 week, may increase to 1000 mg once daily. Mania: Initial: 25 mg/kg once daily, Max: 60 mg/kg/day

Suitable For
Women, Adults, Aged Person, Suitable For All, Children, Teenagers

Divalproex Sodium 250 mg & 500 mg (Sustained Release) Trade Information

Payment Terms
Paypal, Western Union, Cash in Advance (CID), Cheque, Cash Advance (CA)

Sample Policy
Sample costs shipping and taxes has to be paid by the buyer

Packaging Details
Alu-Alu,10*10 Packing

Main Export Market(s)
Western Europe, Asia, North America, Eastern Europe, Middle East, Central America, South America, Australia, Africa

Main Domestic Market
All India

Certifications
WHO-GMP

About Divalproex Sodium 250 mg & 500 mg (Sustained Release)

Divalproex Sodium 250 mg & 500 mg (Sustained Release) is a specific drug formulated as sustained-release tablets to cater to diverse needs, including epilepsy, migraine, and mania management. Recommended for children, teenagers, adults, women, and aged persons, it ensures suitability for all age groups. For epilepsy, the initial dosage is 10-15 mg/kg/day, adjustable by 5-10 mg/kg/week as needed. For migraine relief, a 500 mg dose once daily may be increased to 1000 mg, while for mania, the initial dosage is 25 mg/kg once daily, with a maximum limit of 60 mg/kg/day. Designed for precision and effectiveness, this pharmaceutical solution leverages Divalproex Sodium (250 mg & 500 mg) as its core ingredient. Its sustained-release formulation optimizes therapeutic consistency, providing effective treatment that aligns with professional medical guidelines.